Effects of chronic HIV-1 Tat exposure in the CNS: heightened vulnerability of males versus females to changes in cell numbers, synaptic integrity, and behavior

Yun Kyung Hahn · Elizabeth M. Podhaizer · Sean P. Farris · Michael F. Miles · Kurt F. Hauser · Pamela E. Knapp

Received: 11 October 2013 / Accepted: 11 November 2013 / Published online: 19 December 2013
© The Author(s) 2013. This article is published with open access at Springerlink.com

Abstract HIV-associated damage to the central nervous system results in cognitive and motor deficits. Anti-retroviral therapies reduce the severity of symptoms, yet the proportion of patients affected has remained the same or increased. Although approximately half of HIV-infected patients worldwide are women, the question of whether biological sex influences outcomes of HIV infection has received little attention. We explored this question for both behavioral and cellular/morphologic endpoints, using a transgenic mouse that inducibly expresses HIV-1 Tat in the brain. After 3 months of HIV-1 Tat exposure, both sexes showed similar reduced open field ambulation. Male Tat^+ mice also showed reduced forelimb grip strength and enhanced anxiety in a light–dark box assay. Tat^+ males did not improve over 12 weeks of repeated rotarod testing, indicating a motor memory deficit. Male mice also had more cellular deficits in the striatum. Neither sex showed a change in volume or total neuron numbers. Both had equally reduced oligodendroglial populations and equivalent microglial increases. However, astrogliosis and microglial nitrosative stress were higher in males. Dendrites on medium spiny neurons in male Tat^+ mice had fewer spines, and levels of excitatory and inhibitory pre- and post-synaptic proteins were disrupted. Our results predict sex as a determinant of HIV effects in brain. Increased behavioral deficits in males correlated with glial activation and synaptic damage, both of which are implicated in cognitive/motor impairments in patients. Tat produced by residually infected cells despite antiretroviral therapy may be an important determinant of the synaptodendritic instability and behavioral deficits accompanying chronic infection.

Keywords Striatum · NeuroAIDS · Tat · HIV-1 · Sex · Behavior

Introduction

Combination antiretroviral therapy (cART) has caused a dramatic decline in human immunodeficiency virus (HIV)-associated dementia and mortality. However, the overall prevalence of more moderate motor and cognitive deficits, collectively termed HIV-associated neurocognitive disorders (HAND), has remained similar in cART treated patients (Robertson et al. 2007; McArthur et al. 2010; Heaton et al. 2011). In resource-limited countries, where estimates are that only 36% of the HIV-positive population receives cART, the severity and/or prevalence of neurocognitive disorders is higher (Nakasujja et al. 2005; Wong et al. 2007; Joint United Nations Programme on HIV/AIDS 2010a; Heaton et al. 2010; Tozzi et al. 2005). HAND occurs even in aviremic, cART-treated individuals,
suggesting that many anti-retroviral regimens fail to reverse neurological damage, even while lengthening survival (Heaton et al. 2010, 2011; McArthur et al. 2010).

Approximately half of the 40 million persons infected with HIV-1 worldwide are women (Joint United Nations Programme on HIV/AIDS 2010a). The incidence of HIV is higher in men compared with women in all ethnic groups in the US (Joint United Nations Programme on HIV/AIDS 2010b; Centers for Disease Control and Prevention 2009) and Europe (European Centre for Disease Prevention and Control/WHO Regional Office for Europe 2011), and most studies on HAND epidemiology in western countries focus on males. Studies both pre- and post-cART have reported no difference in rate of HIV-associated neurocognitive complications between sexes in the United States (Robertson et al. 2004; Bouwman et al. 1998). In other studies, the pre- and post-cART risk of similar complications in both developed and resource-limited regions was reportedly higher in females (Wojna et al. 2006; Chiesi et al. 1996; Gupta et al. 2007; Hestad et al. 2012). In contrast, Joska (Joska et al. 2011) found the male genotype to be associated with HIV-related cognitive dysfunction, and Liu (Liu et al. 1996) reported that male HIV$^+$ injection drug abusers had higher cognitive impairment rates. A recent survey of HIV status among patients in the National Epidemiological Survey on Alcohol and Related Conditions found HIV$^+$ males but not HIV$^+$ females had higher rates of mood, anxiety, and personality disorders than their same-sex HIV$^-$ counterparts, even when adjusted for socio-demographic factors (Lopes et al. 2012). Disparities between the sexes in health care services and access to HIV treatment may be confounds, as globally, HIV-infected women are more likely to live in poverty, and have lower literacy levels, higher injection drug abuse rates, and poorer mental health. These considerations might significantly influence either CNS vulnerability to HIV, or a diagnosis of neurocognitive disability (Basso and Bornstein 2000; Farinpour et al. 2003; Maki and Martin-Thormeyer 2009).

We utilized a mouse model with conditional expression of HIV-1 Tat$^{1–86}$ in the CNS to test whether biological sex can influence HIV-related motor and cognitive outcomes. Intriguingly, males showed more impairment in motor, learning, and anxiety tests. Since multiple brain regions are undoubtedly involved in such varied deficits, we specifically examined striatum, which is clearly impacted by HIV and is also involved as a coordinating center in multiple motor, memory, and motivational/emotional tasks and behaviors. At a cellular level, Tat induction significantly altered non-neuronal populations in both sexes. Importantly, males had greater increases in astroglia and activated microglia, and increased TUNEL$^+$ neurons. Dendritic spine density was decreased more significantly in Tat$^+$ males, and both inhibitory and excitatory pre- and post-synaptic proteins were more significantly altered.

The substantial changes in synaptic organization observed in male mice after chronic HIV-1 Tat exposure may make males more vulnerable to motor and social/cognitive behavioral impairment. We propose that HIV-1 Tat differentially affects aspects of inflammation and glial reactivity/remodeling in males and females and that these factors may underlie sex differences in synaptic reorganization and behavioral impairment in Tat transgenic mice, and perhaps also in neuroAIDS patients.

Materials and methods

Animal studies were approved by the Institutional Animal Care and Use Committee at Virginia Commonwealth University.

Animals

Doxycycline (DOX)-inducible HIV-1$_{IIIb}$ Tat$^{1–86}$ transgenic mice were generated as described (Hauser et al. 2009; Fitting et al. 2010b, 2013; Bruce-Keller et al. 2008). Since tat transgene activity is controlled by the glial fibrillary acidic protein (GFAP) promoter, Tat protein expression in the CNS is limited to astroglia. All mice were genotyped to confirm the presence of tat and rtTA transgenes. Chronic CNS Tat expression was induced by feeding chow containing DOX (Harlan Laboratories, Inc., Indianapolis, IN; 6 g/kg) to mice starting at 3 months of age for a 12-week period. Control Tat$^-$ mice were also fed DOX-chow to control for off-target drug effects. In some behavior studies (grip strength, open field test, light/dark box test), other mice of the same age and genotype received normal chow through the experimental period so that data could be normalized. All mice were fed ad libitum. Mice were habituated to the study room for 60 min before all behavior tests. GFAP transcription is sensitive to levels of many hormones and growth factors, yet basal levels of GFAP transcription using such promoters were reported to be roughly similar in males and females in several studies (Cordeau et al. 2008; Cho et al. 2009; Lundkvist et al. 1999). Doxycycline pharmacokinetics in males and females are also similar (Binh et al. 2009).

Rotarod assay

An accelerating rotarod assay was used to evaluate motor performance/coordination and motor memory (Shiotsuki et al. 2010; Brooks and Dunnett 2009; Liu et al. 2010; Jones and Roberts 1968), which are adversely affected in HAND (Tozzi et al. 2005; Goodkin et al. 1997; Simioni et al. 2010). All mice were naïve to the apparatus until the first test day. The Rotamex-5 treadmill (Columbus...
Instruments, Columbus, OH) consists of a rubber-surfaced, 3.0-cm diameter cylindrical treadmill connected to a computer-controlled stepper motor-driven drum. For each trial, mice were placed in individual compartments; the rod was gradually accelerated from 1 to 40 rpm, in 1 rpm increases per 15 s. Acceleration continued until 40 rpm was reached or the animal fell from the rod. Falls were detected by sensors at the bottom of each compartment. Rotarod testing began after 1 week DOX treatment, and was performed once per week for 4 weeks (13–16 weeks of age). After a 4-week break, testing was resumed during the third month of DOX treatment (21–24 weeks of age).

Forelimb grip strength test

Forelimb grip strength was measured as a second indication of potential motor deficits (Chatillon® DFE II grip strength meter, Ametek Test and Calibration Instruments, Largo, FL). Mice were held near the tail base and lowered toward the apparatus until the bar was gripped firmly with both forepaws. The mouse was then gently, but steadily, pulled away from the bar until both forepaws released. Peak force disturbance was automatically registered in grams-force (gf). Each mouse was tested five times in quick succession; the strongest measurement was taken as the score (reviewed by Crabbe et al. 2003). Grip strength was normalized by body weight (g) for statistical comparison.

Open field and light/dark box testing

Open field and light/dark box tests are based upon the rodent’s innate conflict between an aversion to exposed spaces and tendency to explore novel environments (Wallace et al. 2008; Cryan and Holmes 2005). The open field test measures changes in overall locomotion and may indicate states such as depression/anxiety that reduce willingness to explore. The test apparatus is a box (30 × 30 × 15 cm) divided into nine squares (Med Associates Inc., St. Albans, VT), enclosed in a larger, sound-attenuating box equipped with overhead lighting and ventilation. In the open-field test, a mouse naive to the test apparatus was placed at its center and habituated for 1 min. Activity over 10 min was then monitored by 16 infrared beam sensors along the X–Y plane (Ramezani et al. 2011; Burger et al. 2005). In the light–dark box adaptation (Crawley and Goodwin 1980; Malmberg-Aiello et al. 2002), the test apparatus described above is separated into two equal compartments by a partition with an opening in the middle; a black plastic roof covers one compartment. Anxious animals tend to avoid exposure by spending more time in the dark (Bourin and Hascoet 2003). Each mouse was placed in the center of the lighted area (facing the darkened area) and allowed to explore the novel environment for 10 min. Activity was monitored as in the open field test. The number of squares crossed in both light and dark regions was recorded for 10 min. For both tests, data from 6-month-old mice that received 12 weeks of DOX treatment were normalized by scores from control age-matched groups fed normal chow.

Stereology

Mice were deeply anesthetized with isoflurane (Baxter, Deerfield, IL, USA) prior to perfusion with 4 % paraformaldehyde (pH 7.4, Sigma-Aldrich Co., St. Louis, MO) in phosphate-buffered saline (PBS). After perfusion, brains were immediately removed and post-fixed in fresh fixative overnight, hemisected, rinsed several times, and left overnight in 15 ml of PBS. The left brain halves were coronally sectioned at 50 μm and stored individually in cryoprotectant [30 % sucrose (w/v), 1 % polyvinylpyrrolidone (v/v), 30 % ethylene glycol (v/v) in 0.05 M phosphate buffer, pH 7.2, all from Sigma] at −20 °C until use. Free-floating sections containing the striatum were stained with Hoescht 33342 (1 μg/ml, 8 min, Molecular Probes Inc., Eugene, OR) for all unbiased stereological estimation. Sections were thoroughly rinsed and then mounted on gelatin-coated SuperFrost Plus slides (VWR Scientific, West Chester, PA) in ProLong Gold anti-fade reagent (Life Technologies, Grand Island, NY, USA), and then air-dried for ≥8 h in the dark. The total number of (Hoescht+) cells in the striatum was estimated using the optical fractionator method (West et al. 1991); the Cavalieri principle was applied to measure striatal volume with assistance from a computerized stereology system (Stereologer, Stereology Resource Center, Chester, MD) (Mouton 2002). Every fifth section was selected from the total sections through the striatum and analyzed to estimate total cell number and striatal volume. Each reference space was outlined at low power (5 ×), and cells were counted using 100 × magnification under oil-immersion. A guard volume of 2.0 μm was used during cell counting to avoid sectioning artifacts, including lost caps and uneven section surfaces. The slides were viewed on a Zeiss Axio-Observer system with integrated Sony 3CCD Exwave HAD camera system (Carl Zeiss, Inc., Thornwood, NY).

Immunohistochemistry and quantification

Perfusion and preparation of tissue sections were performed as described for stereology. 10 μm frozen or 50 μm free-floating sections were permeabilized with 0.2 % Triton X-100 in phosphate-buffered saline containing 1 % bovine serum albumin (Sigma-Aldrich) for 30 min. To assess proportional numbers of specific cells in the striata, single- or double-label immunostaining was performed. Primary antibodies specific for neuron-specific enolase (NSE; 1:100, Abcam, Cambridge, MA), neuron nuclei (NeuN; 1:200, Millipore, Temecula, CA), oligodendrocyte...
transcription factor 2 (Olig2; 1:100, Immuno-Biological Laboratories, Minneapolis, MN), aldehyde dehydrogenase family 1 member L1 (ALDH1L1; 1:500, Abcam), ionized calcium binding adaptor molecule 1 (Iba-1; 1:200, Wako, Osaka, Japan), and 3-nitrotyrosine (3-NT, 1:100, Santa Cruz Biotechnology, Inc., Santa Cruz, CA) were applied to sections. For double immunostaining, individual primary antibodies were sequentially applied and incubated overnight at 4 °C in a humidified chamber, followed by host-matched fluorescent-conjugated secondary antibodies (1 h, room temperature; Life Technologies). Immunostained sections were then incubated with Hoechst 33342 dye (1 μg/ml, 8 min; Life Technologies) to identify nuclei, rinsed thoroughly, mounted in ProLong Gold anti-fade reagent (Life Technologies), and then air-dried for ≥8 h in the dark. To verify the proportion of neurons, oligodendrocytes, astrocytes and microglia in the striata, 300–350 cells were randomly selected per striatum and assessed for NSE, Olig2, ALDH1L1, and Iba-1 expression, respectively (n = 5–7). To determine the relative activation state of microglia, an independent group of 200 Iba-1+ cells were randomly selected per striatum and assessed for 3-NT expression. Striata were examined under oil immersion at 100× using a Zeiss AxioObserver system with integrated MRm camera system.

Striatal neuron death

Neuron death was assessed by labeling for terminal deoxynucleotidyl transferase-mediated UTP nick end-labeling (TUNEL) followed by NeuN and Hoechst staining. A monoclonal antibody to NeuN and Hoechst 33342 (Life Technologies) were applied to 10 μm frozen coronal sections that included the striatum from all DOX treated groups as described above. TUNEL detection of in situ DNA fragmentation was performed in accordance with procedures in the In Situ Cell Death Detection Kit, TMR red (Roche Applied Science, Indianapolis, IN) in the same slides. To quantify active neuron death, the proportion of cells that were both TUNEL+ and NeuN+ was determined by counting at least 200 NeuN+ cells in adjacent fields in two different sections per animal (n = 6), at 63× magnification. To determine neuron death, 200 NeuN+ cells were randomly selected for assessment of TUNEL (n = 6).

Immunoblotting

In vivo astrocytic markers and pre-/postsynaptic vesicle-associated proteins were examined by immunoblotting in striatal samples from all DOX treated groups (n = 6). Striata were freshly harvested and homogenized (T-PER Reagent, Thermo Scientific, Pittsburgh, PA), including a protease inhibitor cocktail (Roche Applied Science). Homogenized tissue lysates were centrifuged and then stored at −80 °C until use. Protein concentration of each sample was measured using the BCA protein assay (Pierce, Rockford, IL). 20 μg of lysates were loaded per well onto 4–20 % Tris–HCl Ready Gels (Bio-Rad Laboratories, Hercules, CA), and Precision Plus Protein Dual Color Standards (Bio-Rad; MW range 10–250 kDa) were used to visualize protein transfer and determine molecular weight. Proteins were transferred to PVDF membranes (Bio-Rad). Antibodies to astrocyte (ALDH1L1, 1:1000, Abcam; GFAP, 1:1000, Millipore) and pre-/postsynaptic [synaptotagmin 2 (Syt2), 1:100, Zebrafish International Resource Center; synapsin (Syn), 1:1,000, Synaptic Systems; gephyrin (Geph), 1:1,000, Synaptic Systems.; post synaptic density protein 95 (PSD-95), 1:3,000, Affinity BioReagents] were used to probe the blots. Anti-GAPDH (1:2,500, Abcam) was used to normalize protein loading. Host-matched IRDye® Infrared Dyes-conjugated secondary antibodies (LI-COR Biotechnology, Lincoln, Nebraska) were applied to visualize each protein band. Protein bands were detected on an Odyssey® Infrared Imaging System and intensity was analyzed by Odyssey 2.0 software (LI-COR).

Morphology of striatal cells

Medium spiny neuron morphology was also assessed in tissues impregnated using a Golgi–Kopsch procedure (Hauser et al. 2009; Fitting et al. 2010b). Briefly, brain tissues were separately prepared from all groups after 10–16 weeks DOX administration (n = 6). Dendrites were assessed in tissues subjected to a modified Golgi–Kopsch procedure that impregnates cell processes of random neurons and glia in their entirety (Hauser et al. 1989, 2009). After 4 % paraformaldehyde perfusion as described above, whole forebrains were isolated and immersed in 2 % potassium dichromate and 5 % glutaraldehyde (v/v) in the dark at room temperature, and silver-impregnated as previously published (Fitting et al. 2010b, 2013). The ratio of dichromate solution to tissue volume was ≥50:1. After 6 days, tissues were gently washed in ultrapure water (3 × 1 min), tissues were gently blotted to remove excessive dichromate solution, and placed in aqueous 0.75 % silver nitrate for 5 days in the dark (50:1 fluid to tissue volume ratio). Intact forebrains were serial-sectioned on a vibrating microtome (Leica VT1200S, Leica Biosystems, Nussloch, Germany) at 110 μm in the coronal plane, dehydrated through graded ethanol, cleared in xylene, and mounted in Permount (Fisher Scientific, Waltham, MA). Wooden tools were used in all tissue handling. Several criteria were used to select dendrites for quantification: (1) the cell must be fully impregnated throughout its entirety (partially/incompletely impregnated cells were not
assessed); (2) the dendrite must be parallel to the plane of the section, as tilted/angled dendrites can foreshorten the dendrite and influence density; (3) the dendrite must be distinct from dendrites on other neurons. Dendrites were considered pathologic when they were either stunted or extremely thin, or had spines that were unevenly distributed or stunted (Fig. 7A, E, F) (Fitting et al. 2010b; Ferrante et al. 1991; McNeill et al. 1988). The density of Golgi-impregnated spines was assessed on third order dendrites (3 dendrites per neuron; 6 neurons per mouse; \( n = 6 \) mice). In some neurons in male mice (but not females), all of the dendrites had gross decreases in spine density (\( \leq 5 \) spines per 10 mM) that were obvious even without counting (Fig. 7F). We purposely left these grossly abnormal neurons out of the measurements of average spine density so as not to unduly bias the results. Instead, those neurons were included in the counts of cells with pathologic dendrites (Fig. 7A).

Electron microscopy

Male transgenic mice exposed to Tat for 2.5 months (\( n = 3 \)) were perfused with 2 % paraformaldehyde/2 % glutaraldehyde in phosphate buffer (pH 7.4, Sigma-Aldrich Co.), and then post-fixed in 1 % osmium tetroxide (OsO\(_4\)) for 1 h. For dehydration, the fixed tissues were processed through graded ethanols and infiltrated overnight in EMbed 812 (EMS, Hatfield, PA). Tissue was embedded in EMbed 812 and polymerized at 60 °C for 1–2 days. Thin sections of 600–700 Å thickness were cut on a Leica EM UC6i ultramicrotome (Leica Microsystems), collected onto formvar-coated grids, and stained with 5 % uranyl acetate and Reynolds’s lead citrate (Reynolds 1963). Sections were observed with a JEOL JEM-1230 TEM (JEOL USA, Inc.) at 2,000–12,000 \( \times \) magnification and images were obtained using a Gatan Ultrascan 4000 digital camera (Gatan Inc., Pleasanton, CA) with DigitalMicrograph\textsuperscript{TM} software (Gatan Inc.).

Statistical analysis

Analyses were done by one way, or main effect analysis of variance (ANOVA) followed by Duncan’s post hoc testing, and \( t \) test using Statistica 6.0 software (Statistica, Tulsa, OK). Student’s \( t \)-test analyses were performed using GraphPad Prism 5 (GraphPad Software, Inc., La Jolla, CA).

Results

Accelerating rotarod assay

Mice exposed to DOX for 12 weeks performed an accelerating rotarod test once/week during weeks 1–4 and 9–12.

All groups except for male Tat\(^+\) mice increased the duration of time spent on the rotarod over the 12 week period (Fig. 1A). Tat\(^+\) males remained on the bar for an average of <200 s at all times. Female and male Tat\(^-\) mice showed longer running times versus the initial trial at all times after

![Fig. 1](https://example.com/fig1.png)
week 4, reaching a maximum mean of 350 s. Female Tat⁺ mice reached a similar maximum running time but required more time to improve from their initial performance. There was also a significant difference between groups for the highest rotation speed reached before falling, which was 14 rpm for male Tat⁺ mice, and 21–24 rpm for all other groups (p < 0.05, one-way ANOVA, Duncan’s post hoc test, n = 6–8, data not shown).

Forelimb grip strength

Forelimb grip strength was assessed in Tat⁺ and Tat⁻ mice fed DOX-containing chow for 12 weeks and in additional groups matched for age, sex, and genotype fed normal chow. Groups receiving normal chow showed no difference in forelimb grip strength after normalizing for body weight. DOX did not influence grip strength in females regardless of transgene expression (Fig. 1B), and Tat⁻ males receiving DOX had values equivalent to females. Forelimb strength was significantly reduced in male Tat⁺ mice receiving DOX (Fig. 1B), who showed the weakest grip strength among all groups receiving DOX.

Open-field and light/dark box test

Open-field exploration of a novel environment was evaluated in Tat⁺ and Tat⁻ mice fed DOX-containing chow for 12 weeks and in additional groups matched for age, sex, and genotype fed normal chow. Total distance traveled in 10 min was significantly reduced in both male and female Tat⁺ mice after chronic Tat induction (Fig. 2A; Supplemental Table 1A), with no additional effect of biological sex.

A standard light/dark box test was performed to test whether HIV-1 Tat exposure induced anxiety-related behavior in a sex-dependent manner. Ambulation in the dark was similar for female Tat⁻ and Tat⁺ mice, and male Tat⁻ mice. However, male Tat⁺ mice had significantly higher ambulation in the dark compared with all other groups, suggesting an increase in anxiety-like behavior due to chronic HIV-1 Tat expression (Fig. 2B, C; Supplemental Table 1B).

Stereological analysis of striatum cell number and volume

The striatal sections examined were centered on the mid-caudate/putamen area, at approximately Section 25 in a mouse stereotaxic atlas (Franklin and Paxinos 1997). Unbiased stereological estimation of Hoechst-stained cells showed more total cells in the striatum of female than male mice irrespective of Tat expression (Fig. 3A), although there was no significant difference in the estimated striatal volume of any group (Fig. 3B).

Effects of chronic Tat induction on total and TUNEL⁺ neuron populations in striata

Two neuron markers were used to assess the effect of chronic Tat induction on the striatal neuron population. Small increases in TUNEL reactivity were measured in both female and male Tat⁺ mice in NeuN⁺ and NSE⁺ (not shown) striatal neurons (Fig. 4A). Although the differences were significant, these TUNEL⁺/NeuN⁺ cells represented <3 % of all NeuN⁺ cells. The proportion of total cells (Hoechst⁺) that were NSE⁺ neurons was unaffected in either sex (Fig. 4B). NSE was used to assess total neurons, since immunostaining in these relatively thick sections was more consistent than with NeuN antibodies.

Effects of chronic Tat induction on oligodendrocyte populations in striata

We examined the population of cells expressing the transcription factor Olig2 after 12 weeks of DOX treatment. Olig2 is a transcription factor expressed in oligodendrocytes at all developmental stages (Woodruff et al. 2001; Ligon et al. 2006). HIV-1 Tat induction significantly decreased populations of Olig2⁺ oligodendroglia in Tat⁺ females and Tat⁺ males with no significant differences due to sex (Fig. 4C). Double-labeling for Olig2 and the mature oligodendrocyte marker CC1/APC shows that >90 % of Olig2⁺ cells are also CC-1/APC⁺ (Fig. 4D).

Effects of chronic Tat induction on astrogliosis

To assess Tat-induced changes in the proportion of astrocytes in striatum, we used two reliable markers of astroglia, GFAP and aldehyde dehydrogenase 1 family, member L1 (ALDH1L1), which may be a more reliable marker in rodent brain (Yang et al. 2011; Cahoy et al. 2008). The proportion of total (Hoechst⁺) striatal cells expressing ALDH1L1 was increased for both Tat⁺ males and females after 12 weeks of DOX treatment. Additionally, there was a sex effect since male Tat⁺ mice had significantly more ALDH1L1⁺ cells compared with female Tat⁺ mice (Fig. 5A). After chronic Tat induction, the intensity of ALDH1L1 bands in immunoblots from tissue lysates of both female and male Tat⁺ mice was increased (Fig. 5B). Those from male Tat⁺ mice were significantly enhanced compared with all other groups (Fig. 5C), suggesting a sex-related interaction on gliosis. GFAP band intensity in Tat⁺ groups was not significantly increased versus the Tat⁻ group of the corresponding sex, although Tat⁺ male mice did have higher GFAP levels than female mice of either genotype. Overall, even considering the differences between GFAP and ALDH1L1 results, male mice show higher astrocyte activation than females (Fig. 5B-D).
Effect of chronic Tat induction on reactive microglia

After 12 weeks DOX treatment, the percent of Iba-1+ cells among total striatal cells of female and male Tat− mice was similar, and Tat induction caused comparable increases in the proportion of Iba-1+ cells (Fig. 6A). 3-NT, a product of tyrosine nitrosylation mediated by reactive nitrogen species such as peroxynitrite (ONOO−) and nitrogen dioxide (NO2), has been used as a marker of nitrosative cellular stress (Ryu and McLarnon 2006; Shavali et al. 2006; Shishehbor and Hazen 2004), particularly in activated microglia. Iba-1/3-NT co-localization was assessed as a measure of microglial activation. Tat induction significantly increased the proportion of microglia expressing 3-NT in both sexes (Fig. 6B, C). There was a significant interactive effect of sex since the proportion of 3-NT+ microglia was higher in male than in female mice (Fig. 6B).

Effect of chronic Tat induction on spine density, morphology, and synaptic proteins

Morphology

A significant increase of medium spiny neurons with pathologic dendrites was observed in Tat+ mice of both sexes, with a slightly greater increase in males versus females (Fig. 7A). This category includes stunted or extremely thin dendrites or those having spines that were unevenly distributed or stunted (Fig. 7E, F). It also includes neurons in which all visible, third-order dendrites had severe spine loss (density ≤5/10 μM; Fig. 7E, F).

Spine density

For each neuron examined, the density of spines was measured on all visible third-order dendrites. Adult mice
normally exhibit spine densities of approximately 15 per 10 μM in such dendrites (Cheng et al. 1997). In 2–5% of neurons in Tat− mice, all visible dendrites had a spine density of less than 5 per 10 μM (Fig. 7F); this level of pathology, which was obvious even without counting, was never seen in Tat− mice. To obtain a more accurate assessment of spine density in the seemingly normal dendrites, neurons with these extremely spine deficiencies were not included in the calculation of average spine densities. Even exclusive of the severely aberrant neurons, average spine density was decreased in Tat− mice. There were significantly fewer spines in males regardless of genotype (Fig. 7B, C).

**Synaptic proteins**

Changes in spine density are likely to affect synaptic organization and function; thus we performed immunoblot analysis to determine if Tat induction affected the stability of either pre- or post-synaptic inhibitory (Syt2, gephyrin) and excitatory (Syn, PSD-95) synaptic proteins. Tat induction altered levels of both inhibitory synaptic proteins, but only in brains of male mice, where Syt2 was increased and gephyrin was reduced (Fig. 8A–C). The excitatory presynaptic Syn protein was decreased in both sexes of Tat− mice; as observed for other parameters including spine density, males were significantly more affected (Fig. 8A, D). Excitatory postsynaptic PSD-95 levels were specifically reduced in Tat− males (Fig. 8A, E).

**Striatal ultrastructure**

Qualitative electron microscopic evaluation revealed several structural anomalies in Tat− male tissue (Fig. 9). Most prominent were seemingly normal capillaries invested by notably swollen astroglial cytoplasm. Expanded, watery astroglial processes were conspicuous throughout an otherwise normal appearing neuropil. The cytoarchitecture of neuron cell bodies appeared largely normal, with perhaps more frequent autophagic inclusions. Axonal damage was noted, as were areas of axons with abnormally thin myelin. Cellular ultrastructure in Tat− mice appeared normal.
Discussion

In the post-cART era, neuroAIDS has become a chronic disease largely characterized by an increased prevalence of milder cognitive and motor disorders (HAND) with less encephalitis (Antinori et al. 2007; McArthur et al. 2010; Sacktor et al. 2001; Gonzalez-Scarano and Martin-Garcia 2005; Woods et al. 2009; Ellis et al. 2007; Wojna et al. 2006; Dore et al. 2003; Lawrence and Major 2002; Grant et al. 1995; Heaton et al. 1995). Although the subset of female HIV patients has expanded, the question of whether sex influences the occurrence and characteristics of neurocognitive dysfunction in HIV+ patients is largely unexplored. Studies on HAND epidemiology in western countries, where the disease is more prevalent in men, focus largely on males. In more resource-limited settings, social variables between the sexes that affect health care access and quality make sex-related disease vulnerabilities difficult to determine. A recent study suggests that overall rates of neuropsychological impairment may not reflect the entire picture; HIV+ men and women may be differentially impaired in certain attention/memory tasks yet show a similar overall decline (Falide-Garrido et al. 2008).

Inducible Tat-transgenic mice are a reasonable model for testing whether sex influences HAND development since they exhibit many neuropathologic and behavioral
The proportion of striatal cells expressing Iba-1 was increased to the same extent in both chronically induced male and female Tat\(^-\) groups compared with their respective Tat\(^+\) controls (***p < 0.01; ***p < 0.001, Duncan’s post hoc test, n = 6–7). B Chronic HIV-1 Tat exposure also induced a significant increase in the production of 3-NT in Iba-1\(^+\) cells of both sexes. Although there was no sex difference in Tat effect on the Iba-1\(^+\) population overall, 3-NT expression within the Iba-1\(^+\) population was significantly higher in male Tat\(^-\) mice than in female Tat\(^+\) mice (*p < 0.05; **p < 0.01; ***p < 0.001, Duncan’s post hoc test, n = 6–7). Thus, HIV-1 Tat exposure appears to enhance microglial numbers equally in both sexes, but to disproportionately enhance the production of nitrosylated species in microglia within male mice. C Fluorescence image of a triple-labeled, Iba-1\(^+\) (green)/3-NT\(^+\) (red) microglial cell. Blue color indicates Hoechst 33342 staining within the nuclei of this cell, and nearby cells that are not Iba-1\(^+\); 3-NT immunostaining within the scant microglial cytoplasm is indicated by the arrow. Note the ramified appearance of the microglial cell, whose processes likely branch out of the field of this 10-μM section. Microglia with a ramified morphology are usually associated with lower levels of activation, and it is interesting that even cells with this morphology have detectable 3-NT.
the main input region for the basal ganglia is also involved in coordinating multiple behaviors. While the striatum is well known to control and modulate movements and tasks involving motor memory, striatal integration is also a key component in executive functions and decision making, and in processing motivational and emotional information relating to reward and anxiety (Voytek and Knight 2010; Balleine et al. 2007; Helfinstein et al. 2012). Unbiased stereological analyses indicated that Tat exposure did not affect either striatal volume or total striatal cell number in either sex. When individual populations of cells were quantified, there were effects of both sex and Tat exposure.
in total NSE
postsynaptic PSD-95 protein was reduced only in male Tat
A
B
C
D
E

Tat
Tat
Tat
Tat
Tat

/**p < 0.01, one-way ANOVA; Duncan’s post hoc test, n = 6) D, E Both female and male Tat+ mice exhibited a decrease in the excitatory postsynaptic protein synapsin 1 (Syn) compared with Tat− mice: levels in male Tat+ mice were significantly less than those in female Tat+ mice. The excitatory postsynaptic PSD-95 protein was reduced only in male Tat+ mice, compared with all other groups. (*p < 0.05, **p < 0.01, one-way ANOVA, Duncan’s post hoc test, n = 6)

(Figs. 4, 5). Tat expression increased the percentage of apoptotic (TUNEL+) neurons, with slightly greater effect on male brains. The increased neuron loss was not reflected in total NSE+ numbers. We interpret this to suggest that neurons may only have started to die relatively recently, which is in keeping with our finding that TUNEL+ striatal neurons were not increased after short-term Tat exposure in these mice (Bruce-Keller et al. 2008). Over time, if
a low rate of neuron death continues in the absence of replacement, the neuron population will eventually be reduced by a significant level. Tat expression also reduced Olig2+ oligodendroglia independent of sex, perhaps relating to reports that HIV-1 Tat reduces young oligodendrocyte proliferation in vitro (Hahn et al. 2012).

In the absence of neuron loss, what might account for observed behavioral deficits? Since we only examined total neurons, changes in subpopulations of striatal neurons affecting behavior may have been overlooked. Another possibility relates to changes in glial populations (Figs. 5, 6). Chronic exposure to Tat expanded the CNS population of ALDH1L1+ astroglia, as previously observed for GFAP+ astroglia after acute Tat exposure (Bruce-Keller et al. 2008). Cell counts and immunoblots generally concurred that astrogial expansion/astrogliosis was greater in males. As in more acute studies (Gupta et al. 2010; Hahn et al. 2010; Fitting et al. 2010c; Suzuki et al. 2011; Bruce-Keller et al. 2008), the microglial population also increased after chronic Tat exposure. Both sexes showed equivalent Iba-1+ cell increases, but 3-NT, a nitrosative product indicative of microglial activation, was specifically elevated in males. Thus, both microglial activation and astrogliosis correlate with altered behavior in male Tat+...
brains. While not proving a causal relationship, the sustained, low levels of inflammation described in HIV brains even after cART treatment do produce cumulative deficits (Heaton et al. 2010, 2011; Cohen et al. 2010; Gongvatana et al. 2013) and would predict this outcome. Additionally, or alternatively, the relative deficits in male behavior might derive from their more significant abnormalities in dendrite structure and levels of specific synaptic proteins (Figs. 7, 8). Chronic Tat exposure reduced the density of spines on striatal medium spiny neurons in both sexes, similar to other reports with Tat, gp120 or HIV (Sa et al. 2004; Fitting et al. 2010b; Viviani et al. 2006). The pattern of loss was remarkably similar to spine changes reported with cortical deafferentation (Cheng et al. 1997), suggesting interruption of normal cortical connections that account for over 80 % of striatal input. The fact that spine loss recovers after a deafferentation injury (Cheng et al. 1997) may be a hopeful sign for the recovery potential of HIV patients. Both spine loss and abnormal dendrite pathology were clearly higher in male mice, which also showed changes in proteins associated with both inhibitory (presynaptic Syt2, postsynaptic gephyrin) and excitatory (presynaptic synapsin, postsynaptic PSD95) synapses. In females, only the excitatory presynaptic protein synapsin was modestly reduced. While HIV exposure may reduce synaptodendritic efficacy in general (Masliah et al. 1997; Everall et al. 1999; Fitting et al. 2013), Tat interactions may specifically affect how efficiently inhibitory versus excitatory information is processed, at least in striatum (Figs. 7, 8) and hippocampus (Fitting et al. 2013). Sex-specific protein alterations may thus contribute to differences in behavioral outcomes. Notably, reversible changes in excitatory synaptic proteins have been reported in vitro (Shin and Thayer 2013; Shin et al. 2012). Changes in synaptic efficiency likely occur before neuron loss, since synaptic protein changes occurred in hippocampus after more acute (10 days) Tat exposure (Fitting et al. 2013).

An extensive literature, both epidemiological and experimental, suggests that males are more vulnerable to trauma and neurodegenerative events/diseases (de Lau and Breteler 2006; Van Den Eeden et al. 2003; Coronado et al. 2011; Mehal et al. 2013). The lower vulnerability of females may be related to the documented neuroprotective role of estrogen in trauma and neurodegenerative studies (Yune et al. 2008; Rau et al. 2003; Roof and Hall 2000; D’Astous et al. 2004; Hoffman et al. 2006; Tang et al. 1996), although recent work emphasizes that sex as an injury variable includes more than single hormone-single receptor interactions, and involves both genomic and non-genomic effects (Cheng and Hurn 2010; Herson et al. 2009). Although a preponderance of evidence suggests that some component of estrogen-mediated protection derives from down-regulation of dopamine transporter function in the striatum (Wallace et al. 2006; Disshon and Dluzen 1999; Murray et al. 2003), other mechanisms are likely involved in striatum and elsewhere, including expression of endogenous anti-oxidants such as paraoxonase 2 (Giordano et al. 2013) and glutathione (Kumar et al. 2011), as well as anti-oxidant enzyme systems (Kumar et al. 2011; Rao et al. 2011). Recent evidence also suggests that a component of estrogen-mediated neuroprotection may be due to promotion of adaptive responses within neurons, and that males and females can respond differently to locally produced steroids versus those produced or delivered systemically (Gillies and McArthur 2010). Estrogens or ER-β signaling has been shown to exert neuroprotective effects on several HIV models including gp120 injection (Corasaniti et al. 2005), and in vitro Tat or gp120 exposure (Russo et al. 2005; Adams et al. 2010, 2012; Wallace et al. 2006; Brooke et al. 1997) potentially by modulating the balance of protective and inflammatory chemokine/cytokines (Corasaniti et al. 2005; Kipp and Beyer 2009; Dhandapani et al. 2005; Bruce-Keller et al. 2007), or reducing oxidative changes in mitochondria (Simpkins et al. 2010). A cautionary note for all HIV studies is the potential for sex differences (Asin et al. 2008; Zhang et al. 2008; Hel et al. 2010; Lee et al. 1997), which may complicate comparisons between epidemiological and experimental studies.

In conclusion, the data support the hypothesis that chronic exposure to HIV-1 Tat may play a significant role in the decline of cognitive and motor function in HIV patients, perhaps related to or driven by changes in specific cell populations. This study has examined cellular changes specifically within the striatum, but the behavioral deficits observed almost certainly will involve pathology in other CNS regions. Sex appears to be an important variable in predicting vulnerability to behavioral deficits, with males being significantly more affected in several standard rodent tests of motor and social/cognitive skills. Males also showed an enhanced state of glial activation and more evidence of synaptic damage, both of which have been related to cognitive and motor impairments in HIV patients. Importantly, Tat will be produced and released by residually infected CNS cells even when new infection is limited by cART (Johnson et al. 2013), suggesting its importance in determining the stability of CNS cell populations and motor and cognitive health during chronic infection.

Acknowledgments We gratefully acknowledge NIH support: DA028461 and NS069216 (PEK); DA018633 and DA027374 (KFH); U01AA016667 (MMF). Electron microscopy was performed at the VCU-Dept. Anatomy and Neurobiology Microscopy Facility, supported in part with funding from NIH-NINDS Center Core Grant 5P30NS047463.

Conflict of interest The authors declare that they have no conflict of interest.
Open Access This article is distributed under the terms of the Creative Commons Attribution License which permits any use, distribution, and reproduction in any medium, provided the original author(s) and the source are credited.

References

Adams SM, Aksenova MV, Aksenov MY, Mactutus CF, Booze RM (2010) ER-β mediates 17β-estradiol attenuation of HIV-1 Tat-induced apoptotic signaling. Synapse 64(11):829–838. doi:10.1002/syn.20793

Adams SM, Aksenova MV, Aksenov MY, Mactutus CF, Booze RM (2012) Soy isoflavones genistein and daidzein exert anti-apoptotic actions via a selective ER-mediated mechanism in neurons following HIV-1 Tat(1-86) exposure. PLoS One 7(5):e37540. doi:10.1371/journal.pone.0037540

Antinori A, Arendt G, Becker JT, Brew BJ, Byrd DA, Chermer N, Clifford DB, Cinque P, Epstein LG, Goodkin K, Gisslen M, Grant I, Heaton RK, Joseph J, Marder K, Marra CM, McArthur JC, Nunn M, Price RW, Pulliam L, Robertson KR, Sacktor N, Valcour V, Wojna VE (2007) Updated research nosology for HIV-associated neurocognitive disorders. Neurology 68(18):1789–1799. doi:10.1212/01.wnl.0000287431.88658.8b

Asin SN, Heimberg AM, Eszterhas SK, Rollenhagen C, Howell AL (2008) Estradiol and progesterone regulate HIV type 1 replication in peripheral blood cells. AIDS Res Hum Retroviruses 24(5):701–716. doi:10.1089/aid.2007.0108

Balleine BW, Delgado MR, Hikosaka O (2007) The role of the dorsal striatum in reward and decision-making. J Neurosci 27(31):8161–8165. doi:10.1523/JNEUROSCI.1554-07.2007

Basso MR, Bornstein RA (2000) Estimated premorbid intelligence mediates neurobehavioral change in individuals infected with HIV across 12 months. J Clin Exp Neuropsychol 22(2):208–218. doi:10.1076/jexn.20000422.2;1-1;FT208

Binh VQ, Chinh NT, Thanh NX, Cuong BT, Quang NN, Dai B, Travers T, Edstein MD (2009) Sex affects the steady-state pharmacokinetics of primamune but not doxycycline in healthy subjects. Am J Trop Med Hyg 81(5):747–753. doi:10.4269/ajtmh.2009.09-0214

Bourin M, Hascoet M (2003) The mouse light/dark box test. Eur J Pharmacol 463(1–3):55–65 pii:S0014299903012743

Bouwman FH, Skolsky RL, Hes D, Selnes OA, Glass JD, Hancock Sproson TE, Royal W, Dal Pan GJ, McArthur JC (1998) Variable progression of HIV-associated dementia. Neurology 58(6):1814–1820

Brooke S, Chan R, Howard S, Sapolsky R (1997) Endocrine modulation of the neurotoxicity of gp120: implications for AIDS-related dementia complex. Proc Natl Acad Sci USA 94(17):9457–9462

Brooks SP, Dunnett SB (2009) Tests to assess motor phenotype in mice: a user’s guide. Nat Rev Neurosci 10(7):519–529. doi:10.1038/nrn2652

Bruce-Keller AJ, Dimayuga FO, Reed JL, Wang C, Angers R, Wilson ME, Dimayuga VM, Scheff SW (2007) Gender and estrogen manipulation do not affect traumatic brain injury in mice. J Neurotrauma 24(1):203–215. doi:10.1089/neu.2006.0163

Bruce-Keller AJ, Turchan-Cholewo J, Smart EJ, Geurin T, Chauhan A, Reid R, Xu R, Nath A, Knapp PE, Hauser KF (2008) Morphine causes rapid increases in glial activation and neuronal injury in the striatum of inducible HIV-1 tat transgenic mice. Glia 56(13):1414–1427. doi:10.1002/glia.20708

Burger ME, Fachinetti R, Zeni G, Rocha JB (2005) Ebsele attenuates haloperidol-induced orofacial dyskinesia and oxidative stress in rat brain. Pharmacol Biochem Behav 81(3):608–615. doi:10.1016/j.pbb.2005.05.002

Cahoy JD, Emery B, Kaushal A, Foo LC, Zamarian JL, Christopherson KS, Xing Y, Labischier KL, Krieg PA, Krupenko SA, Thompson WJ, Barres BA (2008) A transcriptome database for astrocytes, neurons, and oligodendrocytes: a new resource for understanding brain development and function. J Neurosci 28(1):264–278. doi:10.1523/JNEUROSCI.4178-07.2008

Carey AN, Sypek EI, Singh HD, Kaufman MJ, McLaughlin JP (2012) Expression of HIV-Tat protein is associated with learning and memory deficits in the mouse. Behav Brain Res 229(1):48–56. doi:10.1016/j.bbr.2011.12.019

Carey AN, Liu X, Mintzopoulos D, Paris JJ, Muschamp JW, McLaughlin JP, Kaufman MJ (2013) Conditional Tat protein expression in the GT-tg bigenic mouse brain induces gray matter density reductions. Prog Neuropsycho pharmacol Biol Psychiatry 43:49–54. doi:10.1016/j.pnpbp.2012.12.018

Centers for Disease Control and Prevention (2009) HIV Surveillance Report: Diagnosis of HIV Infection and AIDS in the United States and Dependent Areas, vol 21. http://www.cdc.gov/hiv/topics/surveillance/resources/reports

Cheng J, Hurn PD (2010) Sex shapes experimental ischemic brain injury. Steroids 75(11):754–759. doi:10.1016/j.steroids.2009.10.014

Cheng HW, Rafols JA, Goshgarian HG, Anavi Y, Tong J, McNeill TH (1997) Differential spine loss and regrowth of striatal neurons following multiple forms of deafferentation: a Golgi study. Exp Neurol 147(2):287–298. doi:10.1006/exnr.1997.6618

Chiesi A, Vella S, Dally LG, Pedersen C, Danner S, Johnson AM, Schwanger S, Goebel FD, Glaser M, Antunes F et al (1996) Epidemiology of AIDS dementia complex in Europe. AIDS in Europe Study Group. J Acquir Immune Defic Syndr Hum Retrovir 11(1):39–44

Cho W, Hagemann TL, Johnson DA, Johnson JA, Messing A (2009) Dual transgenic reporter mice as a tool for monitoring expression of glial fibrillary acidic protein. J Neurochem 110(1):343–351. doi:10.1111/j.1471-4159.2009.06146.x

Cohen RA, Hazraek J, Gongvatana A, Buchthal S, Schifitto G, Clark U, Paul R, Taylor M, Thompson P, Tate D, Alger J, Brown M, Zhong J, Campbell T, Singer E, Daar E, McMahon D, Tso Y, Yiamoutsos CT, Navia B (2010) Cerebral metabolite abnormalities in human immunodeficiency virus are associated with cortical and subcortical volumes. J Neurovirol 16(4):353–444. doi:10.1099/jn.0.01552084

Corasaniti MT, Amantea D, Russo R, Piccirilli S, Leta A, Corazzari M, Nappi G, Bagetta G (2005) 17β-estradiol attenuation of HIV-1 Tat-(1-86) induced apoptotic signaling. Synapse 64(11):829–838. doi:10.1002/syn.20793

Cryan JF, Holmes A (2005) The ascent of mouse: advances in modelling human depression and anxiety. Nat Rev Drug Discov 4(9):775–790. doi:10.1038/nrd1825
D’Astous M, Morissette M, Di Paolo T (2004) Effect of estrogen receptor agonist treatments in MPTP mice: evidence of neuroprotection by an ER α agonist. Neuropharmacology 47(8):1180–1188. doi: 10.1016/j.neuropharm.2004.08.020

de Lau LM, Breteler MM (2006) Epidemiology of Parkinson’s disease. Lancet Neurol 5(6):525–535. doi: 10.1016/S1474-4422(06)70471-9

Dhandapani KM, Wade FM, Mahesh VB, Brann DW (2005) Astrocyte-derived transforming growth factor-β mediates the neuroprotective effects of 17β-estradiol: involvement of nonclassical genomic signaling pathways. Endocrinology 146(6):2749–2759. doi: 10.1210/en.2005-0014

Dishon KA, Dluzen DE (1999) Use of in vitro superfusion to assess the dynamics of striatal dopamine clearance: influence of estrogen. Brain Res 842(2):399–407 pii: S0006-8993(99)01863-6

Dore GJ, McDonald A, Li Y, Kaldor JM, Brew BJ (2003) Marked improvement in survival following AIDS dementia complex in the era of highly active antiretroviral therapy. AIDS 17(10):1539–1545. doi: 10.1097/01.aids.0000076282.54156.c3

Ellis R, Langford D, Masliah E (2007) HIV and antiretroviral therapy in the brain: neuronal injury and repair. Nat Rev Neurosci 8(1):33–44. doi: 10.1038/nrn2040

European Centre for Disease Prevention and Control/WHO Regional Office for Europe (2011) HIV/AIDS surveillance in Europe 2010. http://www.ecdc.europa.eu/en/publications/publications/2011/11129_sur_annual_hiv_report.ppd

Fitting S, Khan AG, Knapp PE, Hauser KF, Keller AJ (2010) HIV-Tat elicits microglial glutamate release: role of NAPDH oxidase and the cystine-glutamate antipporter. Neurosci Lett 485(3):233–236. doi: 10.1016/j.neulet.2010.09.019

Gupta JD, Satishchandra P, Gopukumar K, Wilkie F, Waldrop-Valverde D, Ellis R, Ownby R, Subbakrishna DK, Desai A, Kamat A, Ravi V, Rao BS, Satish KS, Kumar M (2007) Neuropsychological deficits in human immuno deficiency virus type 1 clade C-seropositive adults from South India. J Neurol 254(5):561–579

Hahn YK, Podhaizer EM, Hauser KF, Knapp PE (2012) HIV-1 alters neural and glial progenitor cell dynamics in the central nervous system: coordinated response to opiates during maturation. Glia 60(12):1871–1887. doi: 10.1002/glia.20840

Hauser KF, Melrose S, LaFave L, Newell KA, Taylor MJ, Collier AC, Gelman BB, Roffman JL, Wadkins Shipp S, Abramson I, Gamst A, Fennema-Notestine C, Jernigan TL, Abramson I, Fennema-Notestine C, Jernigan TL, Franklin KBI, Paxinos G (1997) The mouse brain in stereotaxic coordinates. Academic Press, San Diego

Gillies GE, McArthur S (2010) Independent influences of sex steroids of systemic and central origin in a rat model of Parkinson’s disease: a contribution to sex-specific neuroprotection by estrogens. Horm Behav 57(1):23–34. doi: 10.1016/j.yhbeh.2009.06.002

Giordano G, Tait L, Furlong CE, Cole TB, Kavanagh TJ, Costa LG (2013) Gender differences in brain susceptibility to oxidative stress are mediated by levels of paraaxonase-2 expression. Free Radic Biol Med 58:98–108. doi: 10.1016/j.freeradbiomed.2013.01.019

Gonzalez-Scarano F, Martin-Garcia J (2005) The neuropathogenesis of AIDS. Nat Rev Immunol 5(1):69–81. doi: 10.1038/nri1527

Goodkin K, Wilkie FL, Concha M, Asthana D, Shapksh P, Doury R, Fujimura RK, LoPiccolo C (1997) Subtle neuropsychological impairment and minor cognitive-motor disorder in HIV-1 infection. Neuropsychological, neurophysiological, neuroimmunological, and virological correlates. Neuroimaging Clin N Am 7(3):561–579

Grant J, Heaton RK, Atkinson JH (1995) Neurocognitive disorders in HIV-1 infection. HNRC Group. HIV Neurobehavioral Research Center. Curr Top Microbiol Immunol 202:11–32

Gupta JD, Atkinson JH, Grant I, Mallory M, Masliah E (1999) Cortical synaptic density is reduced in mild to moderate human immunodeficiency virus neurocognitive disorder. HNRC Group. HIV Neurobehavioral Research Center. Brain Pathol 9(2):209–217

Hauser KF, Hahn YK, Adjan VV, Zou S, Buch SK, Nath A, Bruce-Keller AJ, Hauser KF, Keller JJ, Bruce-Keller AJ (2010) HIV-1 Tat elicits microglial glutamate release: role of NAPDH oxidase and the cystine-glutamate antipporter. Neurosci Lett 485(3):233–236. doi: 10.1016/j.neulet.2010.09.019

Hahn YK, Hauser KF, Knapp PE (2010) β-Chemokine production by neutral and glial progenitor cells is enhanced by HIV-1 Tat: effects on microglial migration. J Neurochem 114(1):97–109. doi: 10.1111/j.1471-4159.2010.06744.x

Hahn YK, Podhaizer EM, Hauser KF, Knapp PE (2012) HIV-1 alters neural and glial progenitor cell dynamics in the central nervous system: coordinated response to opiates during maturation. Glia 60(12):1871–1887. doi: 10.1002/glia.22403

Hauser KF, McLaughlin PJ, Zagon IS (1989) Endogenous opioid systems and the regulation of dendritic growth and spine formation. J Comp Neurol 281(1):397–410. doi: 10.1002/cne.902810103

Hauser KF, Hahn YK, Adjan VV, Zou S, Buch SK, Nath A, Bruce-Keller AJ, Knapp PE (2009) HIV-1 Tat and morphine have interactive effects on oligodenocyte survival and morphology. Glia 57(2):194–206. doi: 10.1002/glia.20746

Heaton RK, Grant I, Butters N, White DA, Kirson D, Atkinson JH, McCutchan JA, Taylor MJ, Kelly MD, Ellis RJ et al (1995) The HNRC 500-neuropsychology of HIV infection at different disease stages. HIV Neurobehavioral Research Center. J Int Neuropsychol Soc 1(3):231–251

Heaton RK, Clifford DB, Franklin DR Jr, Woods SP, Ake C, Vaidya F, Ellis RJ, Letendre SL, Marcotte TD, Atkinson JH, Rivera-Mindt M, Vigil OR, Taylor MJ, Collier AC, Marra CM, Gelman BB, McArthur JC, Morgello S, Simpson DM, McCutchan JA, Abramson I, Fennema-Notestine C, Jernigan TL.
Wong, J., Grant, I. (2010) HIV-associated neurocognitive disorders persist in the era of potent antiretroviral therapy: CHARTER Study. Neurology 75(23):2087–2096. doi: 10.1212/WNL.0b013e318200d4727

Heaton, R.K., Franklin, D.R., Ellis, R.J., McCutchan, J.A., Letendre, S.L., Leblanc, S., Corbhan, S., Duarte, N.A., Clifford, D.B., Woods, S.P., Collier, A.C., Marra, M.C., Morgello, S., Mindt, M.R., Taylor, M.J., Marcotte, T.D., Atkinson, J.H., Wolfson, T., Gelma, B.B., McArthur, J.C., Simpson, M.A., Abramson, I., Gasmi, A., Fennema-Notestine, C., Jernigan, T.L., Wong, J. (2011) HIV-associated neurocognitive disorders before and during the era of combination antiretroviral therapy: differences in rates, nature, and predictors. J Neurovirol 17(1):3–16. doi:10.1007/s13365-010-0006-1

Hefnervin, S.M., Fox, N.A., Pine, D.S. (2012) Approach-avoidance and the role of the striatum in the temperament of behavioral inhibition. Dev Psychol 48(3):815–826. doi:10.1037/a0026402

Herson, P.S., Koerner, I.P., Hurn, P.D. (2009) Sex, sex steroids, and brain injury. Semin Reprod Med 27(3):229–239. doi:10.1055/s-0029-1216276

Hestad, K.A., Menon, J.A., Silalouke-Ngoma, M., Franklin, D.R. Jr., Imasiku, M., Menon, J.A., Silalukey-Ngoma, M., Franklin, RJ. Jr., Imasiku, M. (2013) Neuropsychological assessment of patients positive for HIV-1 infection. J Neural Transm (Vienna) 120(1):75–80. doi:10.1007/s00702-012-0975-5

Johnson, T.P., Patel, K., Johnson, K.R., Maric, D., Calabresi, P.A., Hasbun, R., Kipp, M., Beyer, C. (2009) Impact of sex steroids on neuroinflammatory activation by HIV-Tat protein. Proc Natl Acad Sci USA 106(1):209–214. doi:10.1073/pnas.0812811106

Jones, B.J., Roberts, D.J. (1968) The quantitative measurement of motor incoordination in naive mice using an accelerating rotarod. J Pharm Pharmacol 20(4):302–304

Joska, J.A., Westgarth-Taylor, J., Myer, L., Hoare, J., Thomas, K.G., Combrinck, M., Paul, R.H., Stein, D.J., Fisher, A.J. (2011) Characterization of HIV-Associated Neurocognitive Disorders among individuals starting antiretroviral therapy in South Africa. AIDS Behav 15(6):1197–1203. doi:10.1007/s10461-010-9744-6

Kim, B.O., Liu, Y., Ruan, Y., Xu, Z.C., Schantz, L., He, J.J. (2003) Neuropathologies in transgenic mice expressing human immunodeficiency virus type 1 Tat protein under the regulation of the astrocyte-specific glial fibrillary acidic protein promoter and doxycycline. Am J Pathol 162(5):1693–1707. doi:10.1016/S0002-9440(03)4304-0

Kipp, M., Beyer, C. (2009) Impact of sex steroids on neuroinflammatory processes and experimental multiple sclerosis. Front Neuroendocrinol 30(2):188–200. doi:10.1016/j.yfrne.2009.04.004

Kumar, P., Kale, R.K., McLean, P., Baquer, N.Z. (2011) Protective effects of 17β estradiol on altered age related neuronal parameters in female rat brain. Neurosci Lett 502(1):56–60. doi:10.1016/j.neulet.2011.07.024

Lawrence, D.M., Major, E.O. (2002) HIV-1 and the brain: connections between HIV-1-associated dementia, neuropathology and neuroimmunology. Microbes Infect 4(3):301–308. doi:10.1016/S1286-4579(02)01542-3

Lee, A.W., Mitra, D., Laurence J. (1997) Interaction of pregnancy steroid hormones and zidovudine in inhibition of HIV type 1 replication in monocytic and placental Hofbauer cells: implications for the prevention of maternal-fetal transmission of HIV. AIDS Res Hum Retroviruses 13(14):1235–1242

Ligon KL, Fancy SP, Franklin RJ, Rowitch DH (2006) Olig gene function in CNS development and disease. Glia 54(1):1–10. doi:10.1002/glia.20273

Liu, X., Marder, K., Stern, Y., Dooneief, G., Bell, K., Todal, G., Joseph, M., Elsaid, W., Williams, JB., Ehrhardt, A., Stein, Z., Mayeux, R. (1996) Gender differences in HIV-related neurological progression in a cohort of injecting drug users followed for 3.5 years. J NeuroAIDS-IDS 4(1):17–30

Liu, M., Choi DY, Hunter RL, Pandya JD, Cass WA, Sullivan PG, Kim HC, Gash DM, Bing G (2010) Trichloroethylen induces dopaminergic neurodegeneration in Fisher 344 rats. J Neurochem 112(3):773–783. doi:10.1111/j.1471-4159.2009.06497.x

Lopes, M., Olsson, M., Rabbkin, J., Hasin, DS., Alegría AA., Lin KH., Grant BF., Blanco C. (2012) Gender, HIV status, and psychiatric disorders: results from the National Epidemiologic Survey on Alcohol and Related Conditions. J Clin Psychiatry 73(3):384–391. doi:10.4088/JCP.10m06304

Lundkvist, J., Sundgren-Andersson AK, Tingsborg S., Ostlund P., Engfors C., Alheim K., Bartfai T., Iverfeldt K., Schulzberg M. (1999) Acute-phase responses in transgenic mice with CNS overexpression of IL-1 receptor antagonist. Am J Physiol 276(3 Pt 2):R644–R651

Maki, PM., Martin-Thormeyer E (2009) HIV, cognition and women. Neuropsych Rev 19(2):204–214. doi:10.1007/s11065-009-0903-2

Malmberg-Aiello, P., Ipponi A., Bartolini A., Schunack W. (2002) Mouse light/dark box test reveals anxiogenic-like effects by activation of histamine H1 receptors. Pharmacol Biochem Behav 71(1–2):313–318. doi:10.1016/S0091-3057(01)00691-8

Masliah, E., Heaton, R.K., Marcotte, T.D., Ellis, R.J., Wiley, C.A., Mallory, M., Achim, CL., McCutchan, J.A., Nelson, J.A., Atkinson, J.H., Grant, I. (1997) Dendritic injury is a pathological substrate for human immunodeficiency virus-related cognitive disorders. HNRC Group. The HIV Neurobehavioral Research Center. Ann Neurol 42(6):969–972. doi:10.1002/ana.410420618

McArthur, J.C., Steiner, J., Sacktor, N., Nath, A. (2010) Human immunodeficiency virus-associated neurocognitive disorders: mind the gap. Ann Neurol 67(6):699–714. doi:10.1002/ana.22053

McNeill, T.H., Brown, S.A., Rafols, J.A., Shoulson, I. (1988) Atrophy of dopaminergic neurodegeneration in Fisher 344 rats. J Neurochem 78(7):629

Mehal JM, Holman RC, Schonberger LB, Sejvar JI (2013) Amyotrophic lateral sclerosis/motor neuron disease deaths in the United States, 1999–2009. Amyotroph Later Scler Frontotemoral Degener. 14(5-6):346-352. doi:10.3109/21678421.2013.787629

Mouton PR (2002) Principles and practices of unbiased stereology: an introduction for biocentists. Johns Hopkins University Press, Baltimore

Murray, HE., Pillai, AV., McArthur, SR., Razvi, N., Datla, KP., Dexter, DT., Gillies, GE. (2003) Dose- and sex-dependent effects of the neurotoxin 6-hydroxydopamine on the nigrostriatal dopaminergic pathway of adult rats: differential actions of estrogen in males and females. Neuroscience 116(1):213–222. doi:10.1016/S0306-4522(02)00578-X

Nakasujja, N., Musisi, S., Robertson, K., Wong, M., Sacktor, N., Ronald A. (2005) Human immunodeficiency virus neurological...
complications: an overview of the Ugandan experience. J Neurol 11(Suppl 3):26–29. doi:10.1007/s00265-005-11782

Ramezani A, Goudarzi I, Lashkarbolouki T, Ghorbaniyan MT, Salmani ME, Abrari K (2011) Neuroprotective effects of the 17β-estradiol against ethanol-induced neurotoxicity and oxidative stress in the developing male rat cerebellum: biochemical, histological and behavioral changes. Pharmacol Biochem Behav 100(1):144–151. doi:10.1016/j.pbb.2011.07.010

Rao AK, Dietrich AK, Ziegler YS, Nardulli AM (2011) 17β-Estradiol-mediated increase in Cu/Zn superoxide dismutase expression in the brain: a mechanism to protect neurons from ischemia. J Steroid Biochem Mol Biol 127(3–5):382–389. doi:10.1016/j.jsbmb.2011.06.008

Rau SW, Dubal DB, Bottner M, Gerhold LM, Wise PM (2003) Estradiol attenuates programmed cell death after stroke-like injury. J Neurosci 23(36):11420–11426

Reynolds ES (1963) The use of lead citrate at high pH as an electron-opaque stain in electron microscopy. J Cell Biol 17:208–212

Robertson KR, Kapoor C, Robertson WT, Fiscus S, Ford S, Hall CD (2004) No gender differences in the progression of nervous system disease in HIV infection. J Acquir Immune Defic Syndr 36(3):817–822

Robertson KR, Smurzynski M, Parsons TD, Wu K, Bosch RJ, Wu J, McArthur JC, Coller AC, Evans SR, Ellis RJ (2007) The prevalence and incidence of neurocognitive impairment in the HAART era. AIDS 21(14):1915–1921. doi:10.1097/QAD.0b013e32828e4e27

Roof RL, Hall ED (2000) Gender differences in acute CNS trauma and stroke: neuroprotective effects of estrogen and progesterone. J Neurotrauma 17(5):367–388

Russo R, Navarra M, Maiuolo J, Rotiroti D, Bagetta G, Corasaniti MT (2005) 17β-estradiol protects SH-SY5Y Cells against HIV-1 gp120-induced cell death: evidence for a role of estrogen receptors. Neurotoxicology 26(5):905–913. doi:10.1016/j.neuro.2005.01.009

Ryu JK, McLarnon JG (2006) Minocycline or iNOS inhibition block 3-nitrotyrosine increases and blood-brain barrier leakiness in amyloid β-peptide-injected rat hippocampus. Exp Neurol 198(2):552–557. doi:10.1016/j.expneurol.2005.12.016

Sa MJ, Madeira MD, Ruela C, Volk B, Mota-Miranda A, Madeira ME, Abrari K (2011) Neuroprotective effects of the 17β-estradiol against ethanol-induced neurotoxicity and oxidative stress in the developing male rat cerebellum: biochemical, histological and behavioral changes. Pharmacol Biochem Behav 100(1):144–151. doi:10.1016/j.pbb.2011.07.010

Shin AH, Thayer SA (2013) Human immunodeficiency virus-1 protein Tat induces excitotoxic loss of presynaptic terminals in hippocampal cultures. Mol Cell Neurosci 54:22–29. doi:10.1016/j.mcn.2012.12.005

Shin AH, Kim HJ, Thayer SA (2012) Subtype selective NMDA receptor antagonists induce recovery of synapses lost following exposure to HIV-1 Tat. Br J Pharmacol 166(3):1002–1017. doi:10.1111/j.1476-5381.2011.01805.x

Shiotsuki H, Yoshimi K, Shimo Y, Funayama M, Takamatsu Y, Ikeda I, Takahashi R, Kitazawa S, Hattori N (2010) A rotarod test for evaluation of motor skill learning. J Neurosci Methods 189(2):180–185. doi:10.1016/j.jneumeth.2010.03.026

Shishibehor MH, Hazen SL (2004) Inflammatory and oxidative markers in atherosclerosis: relationship to outcome. Curr Atheroscler Rep 6(3):243–250

Simioni S, Cavassini M, Annoni JM, Rimbaud Abraham A, Bourquin I, Schiffer V, Calmy A, Chave JP, Giacobini E, Hirschel B, Du Pasquier RA (2010) Cognitive dysfunction in HIV patients despite long-standing suppression of viremia. AIDS 24(9):1243–1250. doi:10.1097/QAD.0b013e328335a47b

Simpkins JW, Yi KD, Yang SH, Dykens JA (2010) Mitochondrial mechanisms of estrogen neuroprotection. Biochim Biophys Acta 1800(10):1113–1120. doi:10.1016/j.bbagen.2009.11.013

Suzuki M, El-Hage N, Zou S, Hahn YK, Sorrell ME, Sturgill JL, Conrad DH, Knapp PE, Hauser KF (2011) Fractalkine/CX3CL1 protects striatal neurons from synergistic morphine and HIV-1 Tat-induced dendritic losses and death. Mol Neurodegener 6:78. doi:10.1186/1750-1266-7-78

Tang MX, Jacobs D, Stern Y, Marder K, Schofield P, Cardone B, Means A, Hase Y, Reuken R (1996) Effect of oestrogen during menopause on risk and age at onset of Alzheimer’s disease. Lancet 348(9025):429–432. doi:10.1016/S0140-6736(96)93356-9

Tozzi V, Balestra P, Serraino D, Bellagamba R, Corpolongo A, Piselli P, Lorenzini P, Visco-Comandini U, Vlassi C, Quartuccio ME, Giulianelli M, Noto P, Galgani S, Ippolito G, Antinori A, Narciso P (2005) Neurocognitive impairment and survival in a cohort of HIV-infected patients treated with HAART. AIDS Res Hum Retroviruses 21(8):706–713. doi:10.1089/aids.2005.21.706

Van Den Eeden SK, Tanner CM, Bernstein AL, Fross RD, Leimpeter A, Bloch DA, Nelson LM (2003) Incidence of Parkinson’s disease: variation by age, gender, and race/ethnicity. Am J Epidemiol 157(11):1015–1022

Viviani B, Gardoni F, Bartesaghi S, Corsini E, Facchi A, Galli CL, Di Luca M, Marinovich M (2006) Interleukin-1β released by gp120 drives neural death through tyrosine phosphorylation and trafficking of NMDA receptors. J Biol Chem 281(40):30212–30222. doi:10.1074/jbc.M602156200

Voytek B, Knight RT (2010) Prefrontal cortex and basal ganglia contributions to visual working memory. Proc Natl Acad Sci USA 107(42):18167–18172. doi:10.1073/pnas.1007277107

Wallace DR, Dodson S, Nath A, Booze RM (2006) Estrrogen attenuates gp120- and tat1-72-induced oxidative stress and prevents loss of dopamine transporter function. Synapse 60(1):60–60. doi:10.1002/syn.20214

Wallace VC, Segerdahl AR, Blackeard J, Pheby R, Rice AS (2008) Anxiety-like behaviour is attenuated by gabapentin, morphine and diazepam in a rodent model of HIV anti-retroviral-associated neuropsychiatric pain. Neurosci Lett 448(1):153–156. doi:10.1016/j.neulet.2008.10.005

West MJ, Slomianka L, Gundersen HJ (1991) Unbiased stereological estimation of the total number of neurons in thalamic sections of the rat hippocampus using the optical fractionator. Anat Rec 231(4):482–497. doi:10.1002/ar.1092310411

Wojna V, Skolasky RL, Hechavarria R, Mayo R, Selnes O, McArthur JC, Melendez LM, Maldonado E, Zorrilla CD, Garcia H, Kraiselburd E, Nath A (2006) Prevalence of human immunodeficiency virus-associated cognitive impairment in a group of Hispanic women at risk for neurological impairment. J Neurovirol 12(5):356–364. doi:10.1089/jnv.2006.12.356

Wong MH, Robertson K, Nakasujja N, Skolasky R, Musisi S, Katabira E, McArthur JC, Ronald A, Sacktor N (2007) Frequency of and risk factors for HIV dementia in an HIV clinic in sub-Saharan Africa. Neurology 68(5):350–355. doi:10.1212/01.wnl.0000252811.48891.6d

Woodruff RH, Tekki-Kessari S, Stiles CD, Rowitch DH, Richardson WD (2001) Oligodendrocyte development in the spinal cord and...
Woods SP, Moore DJ, Weber E, Grant I (2009) Cognitive neuropsychology of HIV-associated neurocognitive disorders. Neuropsychol Rev 19(2):152–168. doi: 10.1007/s11065-009-9102-5

Yang Y, Vidensky S, Jin L, Jie C, Lorenzini I, Frankl M, Rothstein JD (2011) Molecular comparison of GLT1+ and ALDH1L1+ astrocytes in vivo in astroglial reporter mice. Glia 59(2):200–207. doi: 10.1002/glia.21089

Yune TY, Park HG, Lee JY, Oh TH (2008) Estrogen-induced Bcl-2 expression after spinal cord injury is mediated through phosphoinositide-3-kinase/Akt-dependent CREB activation. J Neurotrauma 25(9):1121–1131. doi: 10.1089/neu.2008.0544

Zhang M, Huang Q, Huang Y, Wood O, Yuan W, Chacecy C, Daniel S, Rios M, Hewlett I, Clouse KA, Dayton AI (2008) β-Estradiol attenuates the anti-HIV-1 efficacy of Stavudine (D4T) in primary PBL. Retrovirology 5:82. doi: 10.1186/1742-4690-5-82

Zou W, Kim BO, Zhou BY, Liu Y, Messing A, He JJ (2007) Protection against human immunodeficiency virus type 1 Tat neurotoxicity by Ginkgo biloba extract EGb 761 involving glial fibrillary acidic protein. Am J Pathol 171(6):1923–1935. doi: 10.2353/apath.2007.070333